-+ 0.00%
-+ 0.00%
-+ 0.00%

Roth Capital Reiterates Buy on Coya Therapeutics, Maintains $12 Price Target

Benzinga·08/24/2026 17:07:14
语音播报
Roth Capital analyst Boobalan Pachaiyappan reiterates Coya Therapeutics (NASDAQ:COYA) with a Buy and maintains $12 price target.